Latest Articles

Publication Date
Clinical Application of Cell Therapy in the Treatment of Female Reproductive Diseases: A Systematic Review.

Reproductive disorders affect millions of women worldwide, playing a crucial role in determining female fertility health and quality of life. Conventional methods such as surgery, hormone therapy, and assisted reproductive …

Published: Sept. 23, 2025, midnight
Challenges in conducting a feasibility randomized controlled trial of medicinal cannabis for endometriosis pain in Australia.

People with endometriosis report consuming cannabis to manage their endometriosis symptoms, however, its efficacy has not been established in clinical studies. This study aimed to determine the feasibility, acceptability, and …

Published: Sept. 23, 2025, midnight
Potential Changes in the Eutopic Endometrium in Endometriosis: A Narrative Review.

Endometriosis is a disease characterized by the presence of ectopic endometrium, mainly within the peritoneal cavity, and is associated with the development of inflammation due to cyclic endometrial alterations. The …

Published: Sept. 22, 2025, midnight
Genmab takes its Profound buy into endometrial | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Genmab takes its Profound buy into endometrial | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Published: Sept. 16, 2025, 3:39 p.m.
How long does combined hormonal therapy suppress AMH levels in women with endometriomas? Results from an exploratory analysis of a clinical trial.

Lower Anti-Müllerian hormone (AMH) levels have been observed in women with ovarian endometriomas (OMA) undergoing combined hormonal contraceptive (CHC) therapy. However, the extent and timing of AMH recovery after CHC …

Published: Sept. 16, 2025, midnight
Efficacy of Elagolix and Relugolix for the Treatment of Pelvic Pain in Patients With Endometriosis: A Systematic Review.

Endometriosis is a chronic gynecological condition commonly associated with pelvic pain, dysmenorrhea, dyspareunia, and infertility. Owing to the limitations and adverse effects of traditional hormonal therapies, this study aimed to …

Published: Sept. 12, 2025, midnight
Endometriosis Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine - Barchart.com

Endometriosis Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Barchart.com

Published: Sept. 3, 2025, 3:30 p.m.
Endometrial Cancer Pipeline Outlook 2025 - Clinical Trials, - openPR.com

Endometrial Cancer Pipeline Outlook 2025 - Clinical Trials, openPR.com

Published: Aug. 20, 2025, 3:46 a.m.
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail

Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences The Globe and Mail

Published: Aug. 6, 2025, 1:11 p.m.
(PDF) Effects of standard and low doses of estradiol on markers of endometrial receptivity in frozen-thawed embryo transfer cycles: Double-blind, randomized clinical trial - researchgate.net

(PDF) Effects of standard and low doses of estradiol on markers of endometrial receptivity in frozen-thawed embryo transfer cycles: Double-blind, randomized clinical trial researchgate.net

Published: July 30, 2025, 3:19 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!